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Abstract
Introduction To obtain strict glucose regulation, an accurate
and feasible bedside glucometry method is essential. We
evaluated three different types of point-of-care glucometry in
seriously ill intensive care unit (ICU) patients. The study was
performed as a single-centre, prospective, observational study
in a 12-bed medical ICU of a university hospital.
Methods Patients with an expected ICU stay of more than 48
hours were included. Because the reference laboratory delivers
glucose values after approximately 30 to 60 minutes, which is
too slow to use in a glucose regulation protocol and for
calibration of the subcutaneous continuous glucose monitoring
system (CGMS) (CGMS System Gold), we first validated the
ICU-based blood gas/glucose analyser ABL715 (part 1 of the
study). Subsequently, part 2 was performed: after inserting (and
calibrating) the subcutaneous CGMS, heparinised arterial blood
samples were drawn from an arterial line every 6 hours and
analysed on both the Precision PCx point-of-care meter using
test strips and on the blood gas/glucose analyser ABL715.
CGMS glucose data were downloaded after 24 to 72 hours.
The results of the paired measurements were analysed as a
scatter plot by the method of Bland and Altman and were
expressed as a correlation coefficient.
Results Part 1: Four hundred and twenty-four blood samples
were drawn from 45 critically ill ICU patients. The ICU-based
blood gas/glucose analyser ABL715 provided a good estimate
of conventional laboratory glucose assessment: the correlation
coefficient was 0.95. In the Clarke error grid, 96.8% of the
paired measurements were in the clinically acceptable zones A
and B. Part 2: One hundred sixty-five paired samples were
drawn from 19 ICU patients. The Precision PCx point-of-care
meter showed a correlation coefficient of 0.89. Ninety-eight
point seven percent of measurements were within zones A and
B. The correlation coefficient for the subcutaneous CGMS
System Gold was 0.89. One hundred percent of measurements
were within zones A and B.
Conclusion The ICU-based blood glucose analyser ABL715 is
a rapid and accurate alternative for laboratory glucose
determination and can serve as a standard for ICU blood
glucose measurements. The Precision PCx is a good alternative,
but feasibility may be limited because of the blood sample
handling. The subcutaneous CGMS System Gold is promising,
but real-time glucose level reporting is necessary before it can
be of clinical use in the ICU. When implementing a glucose-
insulin algorithm in patient care or research, one should realise
that the absolute glucose level may differ systematically among
various measuring methods, influencing targeted glucose levels.
Introduction
Critical illness is often accompanied by acute hyperglycaemia,
which appears to be a negative prognostic factor for critically
ill patients [1-4]. Worse outcome in hyperglycaemic patients
has been explained mainly by complications such as infections
and decreased wound healing [5]. Moreover, acute hypergly-
caemia has a direct effect on the culprit organ(s). A factor that
may also contribute to bad prognosis is still the apparent lack
of treatment of acute hyperglycaemia.
Recent research suggests that glycaemic control in specific
groups of patients reduces morbidity and even mortality. Van
den Berghe et al. [6] showed that blood glucose regulation
toward normoglycaemia decreased mortality and morbidity in
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a cardiosurgical intensive care unit (ICU) population. Krinsley
[7] found a beneficial effect of glucose regulation on mortality
in a study using a historical control group. However, in a retro-
spective study of 1,085 consecutive mixed ICU patients (mor-
tality 20%), using a multivariate analysis model,
hyperglycaemia was not an independent factor contributing to
mortality [8]. In a recent prospective study in a medical ICU
population, van den Berghe et al. [9] found that reduced blood
glucose levels did not significantly reduce in-hospital mortality
for the whole group, only for the subgroup of patients with an
ICU stay of 3 days or more. So, the available incidence is
inconsistent in regard to the beneficial effects of normoglycae-
mia. Further progress in establishing the role of glycaemic con-
trol in critically ill patients certainly requires an excellent
glucose measuring and reporting system. It should give fast
and reliable results that can be used in a nurse-driven insulin
infusion algorithm that reduces hyperglycaemia without induc-
ing hypoglycaemia [10,11].
A central hospital laboratory delivers glucose values after
approximately 30 to 60 minutes, which is too slow to use in a
glucose regulation protocol. Literature on point-of-care testing
reveals varying accuracy of different handheld meters [12].
The ABL blood gas/glucose analyser used in the study of van
den Berghe et al. [6], to our knowledge, has not been validated
in a critically ill ICU population. Before implementation of a
strict glucose protocol in our ICU, we chose to evaluate accu-
racy and feasibility of the ICU-based blood gas/glucose ana-
lyser ABL715; afterward, we tested the reliability of a
contemporary handheld point-of-care meter using test strips
(Precision PCx; Abbott Diabetes Care, Amersfoort, The Neth-
erlands) and a subcutaneous continuous glucose monitoring
system (CGMS) (CGMS System Gold; Medtronic MiniMed,
Inc., Northridge, CA, USA).
Materials and methods
Patients with an expected ICU stay of more than 48 hours
were included. Data were collected prospectively. No formal
glucose regulation protocol was used; as a rule, continuous
insulin infusion therapy was initiated at blood glucose levels
exceeding 9 to 10 mmol/l (162 to 180 mg/dl) with a blood glu-
cose target between 6 and 8 mmol/l (at the discretion of the
attending physician or nurse). We first validated the ICU-
based blood gas/blood glucose analyser ABL715 against the
central hospital laboratory (part 1 of the study). Heparinised
arterial blood samples were drawn from an arterial line every 6
hours by the same nurse practitioner. One part was sent in a
vacuum-sealed plasma separation tube to the central hospital
laboratory and analysed by a laboratory technologist using a
conventional blood glucose analyser (YSI 2300; Yellow
Springs Instruments, Yellow Springs, OH, USA). The YSI ana-
lyser uses glucose oxidase to measure the glucose concentra-
tion in whole blood (by generation of hydrogen peroxide and
gluconic acid from glucose and oxygen via the enzyme glu-
cose oxidase). The other part was immediately analysed on the
blood gas/blood glucose analyser ABL715.
Next, part 2 was performed. After inserting (and calibrating)
the subcutaneous CGMS System Gold, heparinised arterial
blood samples were drawn from an arterial line every 6 hours
and analysed by both the Precision PCx point-of-care meter
using test strips and the blood gas/glucose analyser ABL715.
CGMS glucose data were downloaded after 24 to 72 hours.
The continuous glucose monitoring system sensor was
inserted in the abdominal subcutis and calibrated every 6
hours according to the manufacturer's indications (using the
ABL715 blood glucose values). ICU nurses inspected the
insertion site twice daily for signs of infection or bleeding. Data
of the CGMS devices were downloaded using the MiniMed
Com-Station® and CGMS Solutions™ software (Medtronic
MiniMed, Inc.). The institutional medical ethical committee was
informed and agreed with the study protocol.
ABL715
The ABL715 Series (Radiometer Medical ApS, Brønshøj,
Denmark) can be set up to measure pH and blood gas and any
combination of oximetry, electrolyte, and metabolite parame-
ters. Glucose concentration is measured by the glucose-oxi-
dase method from 95 µl of whole blood to provide results
within 2 minutes. Maintenance, calibration, and quality control
are performed on a regular basis by the central hospital labo-
ratory. The ABL715 has the capability of cross-linking
between the hospital and laboratory information systems, mak-
ing manual data entry into medical records superfluous. The
network connectivity reduces the workload by automating
data collection.
Precision PCx
The Precision PCx point-of-care system (Abbott Diabetes
Care) is a portable, glucose oxidase-based, whole-blood test-
ing system using test strips, requiring 3.5 µl of whole blood to
provide results within 20 seconds. Results of 4,000 tests can
be stored in the monitor itself. The monitor also features a data
port and a docking station to automatically download these
results in the laboratory or hospital information systems.
According to the manufacturer, glucose levels can be meas-
ured between 1.1 and 75 mmol/l (20 to 600 mg/dl).
Continuous Glucose Monitoring System
The CGMS System Gold features a sensor that can be used
for up to 72 hours. The sensor consists of a flexible, platinum-
plated electrode residing inside a permeable membrane and is
inserted in the subcutaneous tissue just under the skin of the
abdomen. Subcutaneous glucose is measured by the glu-
cose-oxidase method, and every 10 seconds an interstitial glu-
cose measurement is sent to a monitor that records an
average glucose value every 5 minutes. Sensor blood glucose
values are calculated using MiniMed Solutions® version 3.0
software. The manufacturer recommends at least fourAvailable online http://ccforum.com/content/10/5/R135
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calibrations a day for the CGMS System Gold. Monitor data
can be downloaded onto a spreadsheet using the MiniMed
Com-Station® and software. The CGMS calculates blood glu-
cose values in the range of 2.2 to 22.2 mmol/l (40 to 400 mg/
dl).
Statistical analysis
Results of paired measurements (laboratory versus ABL715,
CGMS versus ABL715, and Precision PCx versus ABL715)
were analysed in three ways. Paired values were plotted on a
Bland-Altman plot, which is a plot of differences expressed as
a percentage of averages between the two methods [13].
The Pearson correlation coefficient (r) between the different
methods was determined by linear regression. Finally, error-
grid analysis was performed to obtain information of clinical
relevance from the measurements [14]. Results are plotted in
zones of different significance: points in zone A have no clini-
cal implications (clinically accurate measurement), and points
in zone B lead to an appropriate clinical decision. Only points
lying in zones C, D, and E would lead to inappropriate interven-
tion or lack of intervention. Zone C means misinterpretation of
euglycaemia for hyper- or hypoglycaemia (unnecessary over-
correction is possible). Points in zones D and E mean overes-
timation of hypoglycaemia or underestimation of
hyperglycaemia, which may lead to dangerous treatment.
Results
Part 1: validation of the blood gas/glucose analyser 
ABL715
Four hundred twenty-four heparinised arterial blood samples
were drawn from 45 critically ill ICU patients aged 32 to 88
years. The Pearson correlation coefficient was 0.95 for the
ABL715 blood gas/glucose analyser versus laboratory values
(Figure 1). In the Clarke error grid, 57.2% of measurements
were in zone A and 96.8% in zones A and B (Figure 2). Mean
laboratory YSI glucose was 7.5 ± 3.1 mmol/l (135 ± 55.8 mg/
dl) versus 8.9 ± 3.4 mmol/l (160.2 ± 61.2 mg/dl) (mean ±
standard deviation [SD]) with the ABL715. Over the whole
range, the ABL715 displayed blood glucose values that were
approximately 18% higher than laboratory values. Only a few
glucose levels were in the hypoglycaemic range. The ICU-
based blood glucose analyser appeared to be a feasible
device that delivers fast and reliable glucose values.
Part 2: patient characteristics
One hundred sixty-five samples were drawn on 1 to 3 subse-
quent days per patient from 19 seriously ill ICU patients (aged
31 to 78 years, ICU stay 2 to 25 days [mean 10.7 days]). ICU
mortality was 36%. (Our mean ICU mortality is approximately
18%.)
Eighteen patients (of a total of 19 patients) were on mechani-
cal ventilation; three patients needed renal replacement ther-
apy (continuous veno-venous hemofiltration). The admission
diagnoses were as follows: pneumonia (3 patients), sepsis (4),
chronic obstructive pulmonary disease with pneumonia (2),
heart failure (2), aspiration pneumonia (2), HELLP (hemolysis,
elevated liver enzymes and low platelet count) syndrome/
acute fatty liver (1), gastric bleeding/shock (1), dystrophia
myotonica (1), polytrauma (1), and lung transplantation (2).
Figure 1
Correlation of laboratory and blood gas/glucose analyser ABL715 Correlation of laboratory and blood gas/glucose analyser ABL715. 
Units for blood glucose are millimoles per litre; for conversion to milli-
grams per decilitre, multiply by 18 (for example, 10 mmol/l = 180 mg/
dl.)
Figure 2
Clarke error grid: laboratory versus blood gas/glucose analyser  ABL715 Clarke error grid: laboratory versus blood gas/glucose analyser 
ABL715. Units are milligrams per decilitre; for conversion to millimoles 
per litre, divide by 18. BG, blood gas.Critical Care    Vol 10 No 5    Corstjens et al.
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Values for the mean ± SD (range) of pH, pO2, and haematocrit
of the glucose blood samples were 7.41 ± 0.08 (7.23 to
7.54), 10.6 ± 2.6 kPa (6.7 to 18.2 kPa), and 0.30 ± 0.06 vol/
vol (0.16 to 0.47 vol/vol), respectively.
Part 2a: validation of the CGMS System Gold
The Pearson correlation coefficient was 0.89 for CGMS ver-
sus blood gas analyser (Figure 3). Ninety-four point three per-
cent of values were inside the 95% confidence interval. In the
Clarke error grid, 87.3% were in zone A and 100% were in the
clinically acceptable zones A and B. The Bland-Altman plot is
shown in Figure 4.
Part 2b: validation of the Precision PCx point-of-care 
meter
The Pearson correlation coefficient was 0.89 for Precision
PCx versus blood gas analyser (Figure 5). Ninety-three point
seven percent of measured values were inside the 95% confi-
dence interval. In the Clarke error grid, 95.4% were in zone A
and 98.7% were in zones A and B. The Bland-Altman plot is
shown in Figure 6.
Discussion
In this study on seriously ill ICU patients, the blood gas/glu-
cose analyser ABL715 appears to be a good alternative for
laboratory testing and can be used for fast and reliable glu-
cose measurements in the ICU. The glucose value is available
to the ICU nurse within 2 minutes and is immediately visible in
the hospital information system. The ABL715 requires a very
small amount of blood; the chance of spilling blood from the
syringe or the device is low.
The nursing staff gave the device a high score in terms of user-
friendliness and feasibility. As a minor point of criticism, it was
mentioned that one ABL715 at a 12-bed ICU occasionally
causes a short waiting time. The blood gas/glucose analyser
ABL715 systematically gives values approximately 18%
higher than the laboratory, although the correlation is very
good. This is important when deciding which blood glucose
target one aims for in a tight glucose regulation protocol
(laboratory value of 6 mmol/l = ABL715 value of approximately
7 mmol/l). When subsequently using this analyser in the ICU,
this difference is of minor importance.
The CGMS System Gold also showed a fair correlation. Sub-
cutaneous placing of the sensor's needle was judged to be
easy by the research nurse who performed the insertions dur-
ing this study. The device has to be calibrated four times a day,
which requires the availability of another fast and validated
blood glucose analyser. This type of CGMS is not yet useful
for a glucose regulation protocol, because it provides no real-
time glucose data. (They have to be downloaded every 24 to
72 hours.) Soon, newer types will be available which will
deliver directly visible 'online' glucose data every 5 minutes.
The Precision PCx point-of-care glucometer showed a fair cor-
relation coefficient, was judged to be user-friendly (in spite of
the use of test strips and the higher chance of spilling blood),
and delivers fast results.
Figure 3
Correlation of blood gas/glucose analyser ABL715 and subcutaneous  CGMS System Gold (mmol/l) Correlation of blood gas/glucose analyser ABL715 and subcutaneous 
CGMS System Gold (mmol/l). CGMS, continuous glucose monitoring 
system.
Figure 4
Bland-Altman absolute variance: blood gas/glucose analyser ABL715  versus subcutaneous CGMS System Gold (mmol/l) Bland-Altman absolute variance: blood gas/glucose analyser ABL715 
versus subcutaneous CGMS System Gold (mmol/l). CGMS, continu-
ous glucose monitoring system.Available online http://ccforum.com/content/10/5/R135
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The turnaround time for glucose determinations by the central
hospital laboratory was 30 to 60 minutes, which is too long for
fast adjustment of the insulin infusion dose or other therapeu-
tic actions as required in a glucose regulation protocol and
might cause excess hypoglycaemia.
Current literature on feasibility of bedside glucometry in criti-
cally ill patients is sparse. In a recent hyperinsulinaemic-eugly-
caemic clamp study in 16 patients with diabetes, Clarke et al.
[15] found good accuracy for the subcutaneous CGMS in the
euglycaemic range: 93.7% of the readings were in error grid
zones A and B. In the hypoglycaemic zone (250 blood glucose
measurements <3.7 mmol/l [<70 mg/dl]), however, they found
the CGMS to be less accurate, with only 62.8% in zones A
and B. Goldberg et al. [16] also investigated the accuracy of
the subcutaneous CGMS System Gold in 21 critically ill
patients admitted to a medical ICU and found a Pearson cor-
relation coefficient of 0.88. Clarke error grid analysis catego-
rised 98.7% within the clinically acceptable zones A and B.
Only four of more than 500 paired readings were in the
hypoglycaemic range in this study [16].
Tang et al. [17] tested six handheld glucose meters and a port-
able glucose analyser. At a glucose concentration of 4.8
mmol/l (86.4 mg/dl) and at a pH between 6.94 and 7.84, glu-
cometry remained accurate. However, at a higher glucose
level of 11.2 mmol/l (200 mg/dl), such extreme pH conditions
significantly lowered its precision [17]. In another study, bed-
side reflectance glucometry in 105 arterial blood samples of
10 critically ill adults showed a correlation coefficient of 0.86
compared with the central laboratory [18]. An early report
described that fingerstick glucometry was inaccurate among
patients in shock [19]. Louie et al. [12] compared two point-
of-care meters using arterial blood samples obtained from 247
critically ill patients and found that 98% to 100% of the Sur-
eStepPro and 91% to 95% of the Precision G measurements
fell within an error tolerance of ± 15% versus the hospital
chemistry analyser. In a study by Maser et al. [20] at a cardio-
vascular ICU, capillary whole-blood glucometry had a correla-
tion coefficient of 0.88 with arterial plasma samples analysed
in the hospital laboratory. In the last study, capillary whole-
blood glucose levels were a mean of 0.5 mmol/l (9 mg/dl)
lower than arterial plasma specimens.
We found, despite the good correlation coefficient, that glu-
cose values measured by the blood gas/glucose analyser
ABL715 were constantly higher than laboratory values and
that glucose concentrations measured by the Precision PCx
and the CGMS System Gold tended to be lower than the
ABL715 values. It is therefore important to realise that defining
targets for glucose regulation (for instance, from 4.4 to 6.1
mmol/l [79.2 to 109.8 mg/dl] [6]) also depends on the specific
analytic method used at a particular ICU.
It could be questioned which error tolerances are acceptable
in a critical care setting. Error tolerance criteria proposed by
Kost et al. [21] are (a) within ± 0.8 mmol/l (15 mg/dl) of the
reference measurement for glucose levels ≤5.6 mmol/l (100
mg/dl) and (b) within approximately 15% of the reference
measurement for glucose levels greater than 5.6 mmol/l (100
mg/dl). The ISO (International Organization for
Standardization) criteria are as follows: if the reference value
is greater than 4.1 mmol/l, the sensor reading should be within
20%; if the reference value is less than 4.1 mmol/l, the sensor
reading should be within ± 0.8 mmol/l.
Figure 5
Correlation of blood gas/glucose analyser ABL715 and Precision PCx  (mmol/l) Correlation of blood gas/glucose analyser ABL715 and Precision PCx 
(mmol/l). CGMS, continuous glucose monitoring system.
Figure 6
Bland-Altman absolute variance: blood gas/glucose analyser ABL715  versus Precision PCx (mmol/l) Bland-Altman absolute variance: blood gas/glucose analyser ABL715 
versus Precision PCx (mmol/l).Critical Care    Vol 10 No 5    Corstjens et al.
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Another way to define the error tolerance and to obtain infor-
mation of clinical relevance from the measurements is to cal-
culate the Clarke error grid for the glucometer that is evaluated
[14]. Defined in this way, all three tested glucometers would
be acceptable for use in critically ill patients. We are not com-
pletely sure whether this is also true in the hypoglycaemic
range, because we did not have many measurements in this
range.
Introducing a glucose regulation protocol requires a fast and
accurate way to measure blood glucose levels. Because
implementing such a protocol would increase nursing work-
load, it has to be feasible as well. This means that, in all likeli-
hood, not the most accurate, but the most feasible and
nevertheless still fairly accurate, glucose analyser would be
chosen. On the other hand, the risk of hypoglycaemic epi-
sodes could increase. In the sedated, critically ill patient,
hypoglycaemic warning symptoms are absent. This means
that, apart from safety rules in the protocol, the glucose ana-
lyser has to be very reliable in the low range too.
We deliberately choose seriously ill ICU patients, as shown in
the patient characteristics, because we aimed to test the reli-
ability of the various analysers under conditions such as shock,
vasopressor use, edema, sepsis, and renal replacement ther-
apy. Our study has too few patients and therefore too little
data points under extreme conditions of pH, temperature,
electrolyte disturbances, and hypoglycaemia to make state-
ments about the reliability of specific analysers under these
circumstances.
Conclusion
The ICU-based blood gas/glucose analyser ABL715 is a rapid
and accurate alternative for laboratory glucose determination
and can serve as a standard for ICU blood glucose measure-
ments. The Precision PCx is a good alternative, but feasibility
is limited because of the blood sample handling. The subcuta-
neous CGMS System Gold is promising, but real-time glucose
level reporting is necessary before it can be of clinical use in
the ICU.
When implementing a glucose-insulin algorithm in patient care
or research, one should realise that the absolute glucose level
may differ systematically among various measuring methods,
influencing targeted glucose levels.
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